Novartis continues to grow with further core margin expansion and achieves important innovation milestones
Yahoo! Finance
Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +4% (cc1, -2% USD) with core operating income growing +8% (cc, 0% USD) IM sales grew +4% (cc, -2% USD) and core operating income +8% (cc, 0% USD), with IM core margin reaching 36.9% (+130 bps cc)Sandoz sales grew +4% (cc, -4% USD) with core operating income decreasing -1% (cc, -8% USD) Operating income declined -13% (cc, -21% USD), mainly due to higher restructuring and impairments. Net income declined -67% (cc, -71% USD), or -9
Continue Reading